Advertisement
Screener

Aura Biosciences, Inc. (AURA) Graph

AURA Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $30.75M; Income tax $29.00K; Net income -$45.64M.
  • 2026-03-31: Research and development $27.96M; Income tax $11.00K; Net income -$33.69M.
  • 2025-12-31: Research and development $21.90M*; Income tax $15.00K*; Net income -$25.56M*.
  • 2025-09-30: Research and development $22.18M; Income tax $26.00K; Net income -$26.13M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentIncome taxNet income
2026-06-30$30.75M$29.00K-$45.64M
2026-03-31$27.96M$11.00K-$33.69M
2025-12-31$21.90M*$15.00K*-$25.56M*
2025-09-30$22.18M$26.00K-$26.13M
2025-06-30$22.88M$48.00K-$27.02M
2025-03-31$23.34M$18.00K-$27.48M
2024-09-30$17.04M$43.00K-$21.04M
2024-06-30$16.88M(m)-$20.34M
2024-03-31$17.05M$46.00K-$19.71M
2023-09-30$15.43M(m)-$18.51M
2023-06-30$15.12M(m)-$18.30M
2023-03-31$14.40M$0.00-$17.47M
2022-09-30$11.29M(m)-$15.90M
2022-06-30$9.51M(m)-$13.47M
2022-03-31$8.28M(m)-$12.84M
2021-09-30$6.37M(m)-$8.84M
2021-06-30$6.63M(m)-$8.85M
2021-03-31$4.18M(m)-$5.93M
2020-09-30$2.85M(m)-$3.63M
2020-06-30(m)(m)-$6.16M
2020-03-31(m)(m)-$7.51M

Revenue and expense 6 month

Period endResearch and developmentIncome taxNet income
2026-06-30$58.71M$39.00K-$79.32M
2025-06-30$46.23M$66.00K-$54.50M
2024-06-30$33.93M$46.00K-$40.04M
2023-06-30$29.52M$0.00-$35.77M
2022-06-30$17.79M(m)-$26.30M
2021-06-30$10.82M(m)-$14.78M

Revenue and expense 9 month

Period endResearch and developmentIncome taxNet income
2025-09-30$68.40M$93.00K-$80.63M
2024-09-30$50.97M$88.00K-$61.09M
2023-09-30$44.95M$0.00-$54.28M
2022-09-30$29.08M(m)-$42.20M
2021-09-30$17.18M(m)-$23.62M
2020-09-30$14.50M(m)-$17.30M

Revenue and expense 12 month

Period endResearch and developmentIncome taxNet income
2025-12-31$90.30M$108.00K-$106.19M
2024-12-31$73.30M$112.00K-$86.92M
2023-12-31$65.23M$137.00K-$76.41M
2022-12-31$42.24M$0.00-$58.76M
2021-12-31$25.16M$0.00-$35.25M
2020-12-31$18.04M$0.00-$22.21M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Allogene Therapeutics, Inc. (ALLO)United States$0.574B-4.33
Prime Medicine, Inc. (PRME)United States$0.557B-3.54
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10
Autolus Therapeutics plc (AUTL)$0.506B-1.52
Entera Bio Ltd. (ENTX)$0.485B
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B